We are live on ! Find out more
BCM

BIOS Capital Management Portfolio holdings

AUM $41.7M
1-Year Est. Return 34.92%
This Fund
S&P 500
This Quarter Est. Return
-7.7%
1 Year Est. Return
+34.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$41.7M
AUM Growth
-$11.2M
Cap. Flow
-$724K
Cap. Flow %
-1.74%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
RNTX
Rein Therapeutics
RNTX
+$1.21M

Top Sells

Rank Stock Value
1
LTRN icon
Lantern Pharma
LTRN
+$1.8M
2
INAB icon
IN8bio
INAB
+$131K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACTU
1
Actuate Therapeutics
ACTU
$23.6M
$15.4M 36.9%
10,049,996
– –
IRD
2
Opus Genetics
IRD
$484M
$15.1M 36.33%
3,683,429
– –
CGTX icon
3
Cognition Therapeutics
CGTX
$97.9M
$6.9M 16.56%
6,000,000
– –
RNTX
4
Rein Therapeutics
RNTX
$61M
$3.1M 7.44%
2,982,375
+1,000,000
+50% +$1.21M
LTRN icon
5
Lantern Pharma
LTRN
$21.7M
$1.04M 2.5%
249,397
-615,038
-71% -$1.8M
INAB icon
6
IN8bio
INAB
$10.4M
$114K 0.27%
80,957
-86,848
-52% -$131K

Similar funds

BP
Baypointe Partners Stamford, Connecticut $41.7M AUM 18.93% 1-Year Est. Return
MAMNY
Marathon Asset Management (New York) New York $41.5M AUM 245.82% 1-Year Est. Return
AP
Atairos Partners Bryn Mawr, Pennsylvania $41.1M AUM 4.36% 1-Year Est. Return
CIC
Cincinnati Indemnity Company Fairfield, Ohio $41.1M AUM 6.63% 1-Year Est. Return
GCM
GuideStone Capital Management Dallas, Texas $42.5M AUM 41.03% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
GC
Gruss & Co West Palm Beach, Florida $40.8M AUM 44% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

BIOS Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, BIOS Capital Management held 6 positions worth $41.7M, down 21% from $52.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2026: portfolio turnover was 0%. BIOS Capital Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BIOS Capital Management added most to Rein Therapeutics in Q2 2026, an estimated $1.21M increase.
  • BIOS Capital Management's biggest Q2 2026 reduction was Lantern Pharma, cutting an estimated $1.8M.
  • BIOS Capital Management's ten largest holdings make up 100% of its $41.7M portfolio in Q2 2026.
  • BIOS Capital Management opened 0 new positions and closed 0 in Q2 2026.
  • BIOS Capital Management's portfolio value fell 21% quarter-over-quarter to $41.7M.

Based on BIOS Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.